基因确诊MODY的人群患病率、外显率与死亡率
致病变异携带率为1/1052,占40岁前诊断糖尿病病例的1.48%;GCK变异最常见(1/2787),外显率高但与非全因死亡率无显著关联,其他MODY基因外显率较低且死亡率无增加。
要点
- MODY致病变异携带率为1/1052,占40岁前糖尿病1.48%。
- GCK变异携带者94.5%有糖尿病或前期,但全因死亡率无显著增加。
- 其他MODY基因携带者40岁和60岁糖尿病累积外显率分别为12%和31.6%。
核心结论
- 基因型优先方法揭示MODY在人群中患病率约为1/1052,不同遗传病因的外显率和死亡率存在差异。
主要发现
- MODY致病变异占40岁前诊断糖尿病病例的1.48%。
- HNF1A外显率最高,PDX1、NEUROD1和RFX6最低。
- 糖尿病家族史和多基因风险是外显率的重要修饰因素(风险比分别为2.54和1.52,P<3.9×10^-3)。
临床怎么用
- 支持在早发糖尿病中进行MODY基因检测以指导个体化治疗和遗传咨询。
- GCK变异携带者虽外显率高但死亡率未增加,可优化管理策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Diagnosing maturity-onset diabetes of the young (MODY) is clinically important for treatment and prognosis. However, phenotype-based studies of MODY are prone to ascertainment bias, limiting accurate estimates of its population prevalence and phenotypic spectrum. OBJECTIVE: To apply a genotype-first approach to determine the population prevalence, penetrance, and all-cause mortality associated with MODY. METHODS: We analyzed exome sequencing and clinical data from 454 275 UK Biobank participants to identify pathogenic variants in 10 established MODY genes. We assessed variant prevalence, age-dependent diabetes penetrance, and all-cause mortality by genetic etiology over a mean follow-up of 13.4 years. RESULTS: Pathogenic MODY variants were present in 1 in 1052 individuals and accounted for 1.48% of diabetes cases diagnosed before age 40. GCK variants were the most frequent (1 in 2787), demonstrating high penetrance (mean HbA1c 8.8 mmol/mol higher; 94.5% with prediabetes or diabetes) but no significant association with all-cause mortality (P = .09). Variants in other MODY genes showed lower penetrance, with 12% of carriers developing diabetes by age 40 and 31.6% by age 60 and showed no increase in all-cause mortality (P = .89). Penetrance varied by genetic etiology, with HNF1A showing the highest penetrance and PDX1, NEUROD1, and RFX6 the lowest. Parental history of diabetes and polygenic risk for type 2 diabetes were important modifiers of penetrance (hazard ratios 2.54 and 1.52, respectively; P < 3.9 × 10-3). CONCLUSION: This large-scale genotype-first study provides novel insights into MODY in the population. These findings have broad implications for genetic counseling, personalized treatment strategies, and healthcare resource allocation.
引用
- Sharp LN, Colclough K, Murray Leech J, et al. Population Prevalence, Penetrance, and Mortality for Genetically Confirmed MODY. J Clin Endocrinol Metab. 2026. PMID: 41175096. doi:10.1210/clinem/dgaf599
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。